PT-141 (Bremelanotide): Melanocortin Receptor Research

Published: March 2026

PT-141, also known by its INN Bremelanotide, is a cyclic heptapeptide melanocortin receptor agonist derived by structural modification of Melanotan II (MT-II). Unlike its linear peptide precursors, PT-141 incorporates a lactam bridge that confers conformational rigidity, improved metabolic stability, and a distinct receptor selectivity profile. The compound has been investigated extensively in preclinical radioligand binding assays, rodent behavioral pharmacology models, and human pharmacokinetic studies, predominantly as a tool compound for probing the melanocortin signaling axis. Its receptor pharmacology — particularly its relative activity at MC3R and MC4R versus the peripheral pigmentation target MC1R — has made it a useful instrument for dissecting the functional anatomy of central melanocortin circuitry in animal model research.

Molecular Profile

Structural Relationship to Melanotan II and α-MSH

The structural lineage of PT-141 originates with alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino acid endogenous peptide produced by post-translational processing of proopiomelanocortin (POMC). α-MSH carries a conserved His-Phe-Arg-Trp (HFRW) pharmacophore that constitutes the minimal recognition motif for melanocortin receptor binding. Early medicinal chemistry work at the University of Arizona, led by Hruby and colleagues, sought to identify conformationally constrained analogs of α-MSH with increased potency and selectivity. The substitution of norleucine at position 4 and D-phenylalanine at position 7 — producing [Nle⁴, D-Phe⁷]-α-MSH, designated superpotent α-MSH or NDP-α-MSH — dramatically increased receptor affinity and resistance to proteolytic degradation. Further cyclization through introduction of an Asp–Lys lactam bridge in the analog MT-II created the cyclic backbone that PT-141 shares.

PT-141 is metabolically derived from MT-II: it is produced by hydrolysis of MT-II’s C-terminal amide, resulting in a free carboxylic acid terminus. This modification reduces melanotropic activity at MC1R (the peripheral skin pigmentation receptor) relative to MT-II while preserving central receptor engagement. Comparative binding studies have documented that PT-141 and MT-II exhibit overlapping but quantitatively distinct receptor selectivity profiles, and this differentiation has been exploited in preclinical research to probe receptor-subtype-specific contributions to behavior in animal models. The cyclic lactam architecture shared by both compounds restricts backbone conformational freedom, stabilizing the biologically active β-turn conformation around the HFRW pharmacophore and conferring resistance to exo- and endopeptidases that limit the in vivo half-life of linear α-MSH analogs.

Melanocortin Receptor Selectivity Profile

The melanocortin receptor family consists of five subtypes (MC1R–MC5R), each with distinct tissue expression patterns and physiological correlates. PT-141 functions as a non-selective melanocortin receptor agonist with highest affinity at MC3R and MC4R, the two subtypes expressed predominantly in the central nervous system. Radioligand competition binding assays using ¹²⁵I-NDP-α-MSH have characterized PT-141’s binding constants across receptor subtypes expressed in heterologous cell systems. Molinoff et al. (2003) reported K_i values for PT-141 at MC1R, MC3R, MC4R, and MC5R, demonstrating that PT-141 exhibits binding affinity at all four assayed subtypes, with EC₅₀ values in the low nanomolar range at MC3R and MC4R in cAMP accumulation assays.

The functional selectivity pattern of PT-141 at MC3R versus MC4R has been of particular interest to researchers. MC4R is highly expressed in hypothalamic nuclei, limbic structures, and brainstem regions, and preclinical pharmacology literature has used selective and non-selective melanocortin agonists to interrogate which receptor subtype mediates specific behavioral and autonomic outputs observed in rodent models following intracerebroventricular (ICV) administration. MC3R, by contrast, is expressed in a partially overlapping but distinct distribution that includes the arcuate nucleus and limbic forebrain. The differential contributions of MC3R and MC4R activation to the outcomes observed in animal model studies remain an active area of investigation, and the non-selective profile of PT-141 across these two subtypes complicates mechanistic attribution in whole-animal experiments.

CNS Receptor Distribution and Neuroanatomical Research

Autoradiographic and in situ hybridization studies have mapped the distribution of MC3R and MC4R across rodent and primate brain regions in detail. Mountjoy et al. (1994) provided an early characterization of MC4R mRNA distribution in the rat brain using Northern blotting and in situ hybridization, identifying dense expression in the hypothalamus, thalamus, brainstem, and spinal cord. This neuroanatomical distribution established a basis for interpreting the behavioral outcomes observed when cyclic melanocortin peptides — including PT-141 and MT-II — are administered centrally in animal models. Subsequent immunohistochemical studies have extended this map, confirming MC4R protein expression in paraventricular hypothalamic neurons, the nucleus tractus solitarius, the dorsal raphe, and spinal autonomic intermediolateral cell columns.

The limbic distribution of MC4R, including expression in the medial amygdala, nucleus accumbens shell, and hippocampal formation, has been of interest in the context of animal behavioral neuroscience. Preclinical studies using MC4R knockout mice and pharmacological blockade with MC4R antagonists such as HS014 or SHU9119 have helped delineate which behavioral outcomes are attributable to MC4R activation versus other melanocortin receptors. PT-141 has been employed in several such studies as the agonist tool compound due to its CNS bioavailability following subcutaneous administration in rodents, a pharmacokinetic property that distinguishes it from larger or more polar peptide analogs with limited blood-brain barrier penetration.

Preclinical Pharmacokinetic Data

Diamond et al. (2004) published pharmacokinetic data from early clinical investigation studies examining PT-141 administered by intranasal and subcutaneous routes in human volunteers under controlled research conditions. Subcutaneous administration produced C_max values typically observed within 60–90 minutes, with a terminal elimination half-life on the order of approximately 2–4 hours. Intranasal delivery yielded lower and more variable systemic exposure with a slower time to peak, consistent with incomplete nasal mucosal absorption. The cyclic lactam structure of PT-141 confers substantially greater proteolytic stability than linear α-MSH analogs: in plasma stability assays, PT-141 is resistant to the N-terminal and C-terminal processing that rapidly degrades α-MSH in serum. This stability profile has facilitated its use in longer-duration animal model studies where repeated or sustained receptor engagement is required.

Radiolabeled tracer studies using ³H- and ¹²⁵I-labeled analogs related to PT-141 have characterized CNS distribution following peripheral administration in rodents, providing evidence for penetration of blood-brain barrier. Plasma protein binding of bremelanotide has been estimated at approximately 21% in in vitro assays, suggesting relatively high free fraction in circulation. Urinary recovery studies identified deacetylated metabolites as primary biotransformation products, with the cyclic lactam bridge remaining intact across the major observed metabolites, consistent with the resistance of the cyclic peptide scaffold to hydrolytic ring-opening under physiological conditions.

Animal Model Behavioral Research and MC4R Pathway Investigation

The most extensively characterized preclinical application of PT-141 has been in animal behavioral pharmacology models investigating the role of CNS melanocortin signaling. King et al. (1996) and subsequent work from Pfaus, Giuliano, and colleagues used ICV and subcutaneous administration of cyclic melanocortin peptides in rat models to characterize the behavioral pharmacology associated with MC3R/MC4R activation in limbic and hypothalamic circuits. These studies employed PT-141 and MT-II as tool compounds alongside receptor-subtype-selective ligands and antagonists to build a mechanistic framework for understanding how melanocortin tone in hypothalamic nuclei influences behavioral and physiological readouts in standardized animal model paradigms.

Giuliano et al. (2006) conducted a systematic series of experiments in rat and rabbit animal models examining central versus peripheral melanocortin receptor contributions to the autonomic and behavioral pharmacology of PT-141. This work demonstrated that intrathecal administration recapitulated spinal cord–mediated autonomic effects, while intracerebroventricular administration engaged supraspinal circuitry, and that specific MC4R antagonist pretreatment attenuated defined components of the measured outcomes — providing evidence for MC4R-mediated contributions at both supraspinal and spinal levels. These mechanistic dissection studies are representative of how PT-141 has been employed as a pharmacological probe rather than a therapeutic candidate in preclinical neuroscience literature.

Comparison to Other Melanocortin Peptides in Binding Assay Research

Systematic structure-activity relationship (SAR) analyses have benchmarked PT-141 against a panel of melanocortin peptides in heterologous receptor expression systems. Chhajlani (1996) and Adan and colleagues have published binding affinity data comparing α-MSH, NDP-α-MSH, MT-II, PT-141, and selective analogs such as MTII-derived cyclic pentapeptides and the MT-II–related compound PL-17 across all five human melanocortin receptor subtypes expressed in transfected HEK293 or CHO cell lines. These datasets have been useful for interpreting in vivo pharmacology by providing the quantitative receptor-subtype binding constants needed to estimate receptor occupancy at given plasma concentrations.

In competitive radioligand displacement assays, PT-141 consistently displays nanomolar K_i values at MC3R and MC4R, with modestly lower affinity at MC1R compared to MT-II — a difference attributed to the structural consequence of the free C-terminal carboxylate in PT-141 versus the C-terminal amide of MT-II on the receptor recognition pharmacophore. At MC2R (the ACTH receptor, expressed primarily in adrenal cortex), neither MT-II nor PT-141 shows meaningful binding activity, consistent with the requirement of the full 13-residue ACTH sequence for MC2R activation. At MC5R, expressed in exocrine glands, PT-141 exhibits binding affinity comparable to its activity at MC3R and MC4R, a consideration relevant to the interpretation of peripheral effects observed in whole-animal pharmacology experiments that use PT-141 as a tool compound.

Key Published References

1. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96–102. PMID: 12851301
2. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51–59. PMID: 14963472
3. Giuliano F, Bernabé J, McKenna K, Longueville F, Rampin O. Spinal proerectile effect of oxytocin in anesthetized rats. Am J Physiol Regul Integr Comp Physiol. 2001;280(6):R1870–R1877. PMID: 11353693
4. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol. 1994;8(10):1298–1308. PMID: 7854347
5. King SH, Mayorov AV, Balse-Srinivasan P, et al. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 2007;7(11):1098–1112. PMID: 17584130
6. Hruby VJ, Sharma SD, Toth K, et al. Design, synthesis, and conformation of superpotent and prolonged acting cyclic lactam analogues of alpha-melanotropin. Ann N Y Acad Sci. 1993;680:51–63. PMID: 8390157
7. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101(27):10201–10204. PMID: 15218100
8. Chhajlani V. Distribution of cDNA for melanocortin receptor subtypes in human tissues. Biochem Mol Biol Int. 1996;38(1):73–80. PMID: 8932523

Product Availability

PT-141 (Bremelanotide) is available for qualified research applications through White Market Peptides: PT-141 — Research Grade.